Monday, March 17, 2025 | 06:52 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Cost, timeline: Facts about Pfizer-BioNTech's '90% effective' Covid vaccine

The companies said the vaccine was more than 90% effective and they have so far found no serious safety concerns, priming it for possible speedy regulatory approvals

Coronavirus, vaccine, covid, drugs, Sepsivac, clinical trials
Premium

Pfizer expects to seek broad U.S. emergency use authorisation in the U.S. of the vaccine for people aged 16 to 85 in coming weeks.

Reuters
U.S. drugmaker Pfizer and German partner BioNTech on Monday became the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine.
The companies said the vaccine was more than 90% effective and they have so far found no serious safety concerns, priming it for possible speedy regulatory approvals.
Pfizer expects to seek broad U.S. emergency use authorisation in the U.S. of the vaccine for people aged 16 to 85 in coming weeks.
To do so, it will need to have collected two months of safety follow-up data on around half of the study's roughly 44,000 participants, expected in

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in